V8 Peptides — Engineered Performance
Research Library
IGF-1 LR3 Complete Guide: Where the Research Fits
IGF-1 LR3Preclinical

IGF-1 LR3 Complete Guide: Where the Research Fits

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What is IGF-1 LR3 and where does it fit in laboratory research? IGF-1 LR3 (Long R3 IGF-1) is an 83-residue recombinant analog of insulin-like growth factor 1, engineered to bind IGF-binding proteins weakly so that more of it stays free to activate the IGF-1 receptor. It belongs to a larger system of ligands, receptors and binding proteins. In the laboratory it appears mainly as a defined growth-factor input for cell culture and as a tool for studying IGF-1 receptor signaling through the PI3K/Akt and Ras/MAPK pathways. This guide maps that landscape and points to deeper articles on each part.

Most pages about IGF-1 LR3 describe the molecule in isolation. This guide takes the opposite approach: it places the analog in the IGF system it was built to work in, sorts the main research contexts in which it appears, and gives a method for reading papers about it. The aim is orientation. Each topic has a dedicated article in the research library, and this page tells you which one to read for which question. For laboratory research use only; not for human consumption.

The IGF system in one page

Insulin-like growth factor 1 acts within a system of components that matter for interpreting any experiment (Laron, 2001; Baxter, 2000).

ComponentWhat it isWhy it matters for an IGF-1 LR3 experiment
IGF-1 and IGF-2Ligands of the systemNative ligands made by many cell types; present in serum and conditioned medium
IGF-1 receptorReceptor tyrosine kinaseMain receptor for IGF-1 and for the analog
Insulin receptor and hybridsRelated receptor; can form IGF-1R hybridsCan be activated by high ligand levels; confounds attribution
IGF-binding proteins 1–6Carriers and modulatorsBind native IGF-1 tightly; the analog was designed to avoid them
Acid-labile subunitPartner of IGFBP-3 in circulating complexesPart of the reservoir that prolongs native IGF-1 in the body
ProteasesCleave binding proteins and ligandsChange how much free ligand is available locally

Every experiment with the analog is, in effect, an experiment on how this system behaves when the binding-protein arm is largely bypassed.

What IGF-1 LR3 is

IGF-1 LR3 is a recombinant analog with 83 amino acids and a mass near 9.1 kDa, compared with the 70-residue native protein. An arginine replaces the glutamate at position 3 and a 13-residue extension is added at the N-terminus. Both changes reduce binding-protein interaction (Bayne et al., 1988; Tomas et al., 1992). The product page lists a 1 mg lyophilized vial with HPLC purity of 98% or higher; sequence and identity are reported on the certificate of analysis where one is published. For sequence-level detail, see the IGF-1 LR3 explainer.

The main laboratory contexts

The analog is used in a few recurring settings. The table shows what each context asks of the reagent and what to read next.

ContextWhat the analog is used forWhat matters mostWhere to read more
Serum-free and low-serum cell cultureA durable growth-factor input that survives binding-protein captureConcentration, adsorption, medium refresh scheduleResearch overview
Receptor signaling studiesActivating IGF-1R and following PI3K/Akt and ERK branchesControls for insulin-receptor cross-activation, time coursesHakuno and Takahashi (2018)
Skeletal muscle cell modelsTesting growth and hypertrophy signaling in cultured myotubesDose and time, serum conditionsRommel et al. (2001)
Animal studies of growth factor actionComparing variants with native IGF-1 in rodentsSpecies, route, binding-protein statusTomas et al. (1992, 1993)
Analytical and quality workVerifying identity, folding and activity of the reagentDisulfide pairing, aggregates, endotoxinPurity testing guide

A short history of the analog, as told by the literature

Work in the late 1980s, such as the analog panel of Bayne and colleagues (1988), showed that modified IGF-1 molecules could lose affinity for serum binding proteins while keeping receptor activity. The 1990s brought comparative animal studies of IGF-1 and its variants in rats, including dexamethasone-exposed and normal animals (Tomas et al., 1992; 1993), and the analog moved into routine use in cell-culture media. Later reviews of IGF-1R signaling (Hakuno and Takahashi, 2018) provide the current picture of the pathways it drives. This is a literature trail, not a claim about any use beyond the laboratory.

How to read a paper about IGF-1 LR3

Ask the same six questions of every paper.

  1. Which molecule? LR3, DES, native IGF-1 or a fragment; the names are often confused.
  2. Which system? Cell line, primary cells, tissue explant or animal, and how much binding protein it contains.
  3. Which readout? Receptor phosphorylation, pathway readout, proliferation or protein synthesis; each has a different time scale.
  4. Which controls? Receptor blockade, pathway inhibitors, a native IGF-1 arm.
  5. How was concentration set? Nominal or measured, and was a carrier present?
  6. Is the conclusion within the evidence? A cell-line result does not describe an organism.

Reading list: which article answers which question

Handling essentials in brief

The product page states refrigerated storage at 2–8 °C, −20 °C for long-term holding, protection from heat, moisture and light, in a sealed clear glass vial. Because the molecule is a folded protein, reconstitution is gentle, stocks are divided into single-use portions, low-binding plastic or carrier protein limits loss at low concentration, and concentration is calculated as mass divided by volume. Stability and handling rationale are expanded in the handling articles above.

Name confusion to watch for

Listings and search results use several overlapping names. "IGF-1" can mean the native 70-residue protein. "IGF-1 LR3" and "Long R3 IGF-1" mean the 83-residue analog described here. "IGF-1 DES" and "des(1-3) IGF-1" mean a truncated variant. "IGF-1 fragment" or "IGF-1 peptide" can be a shorter piece with different properties, and the phrase is sometimes used loosely for any of the above. The reliable identifiers are the declared compound name, the number of residues, the molecular formula or mass, and the certificate where one is published. Before comparing papers or products, reduce each to those four facts and check that they match.

Questions to settle before designing an experiment

A short pre-experiment checklist saves repeated work. What is the readout and on what time scale will it change? Does the system contain binding proteins, and if so how much? Is insulin receptor cross-activation a concern at the concentrations planned? How will the stock be prepared, what is its measured concentration, and how many experiments must it cover? What reference will the result be compared with: native IGF-1, a previous lot, or a vehicle control? Writing the answers down turns a vague plan into a protocol that another person could repeat, and it makes the later review of an unexpected result much easier.

Limits of the evidence

Most of what is known about IGF-1 variants comes from cell culture and rodent studies, and much of the signaling literature uses native IGF-1 rather than the LR3 analog. Reported potency advantages depend on binding-protein content; findings from one species or cell type do not transfer automatically; and reagent quality, including folding and aggregation, can alter results. A reproducibility lens is useful here: variation in biological reagents is a recognized contributor to results that cannot be repeated (Freedman et al., 2015). Document the lot, the handling and the controls so that your own results can be interpreted later. When a result differs from a published one, the first things to compare are the molecule actually used, the binding-protein content of the system, the concentration as measured rather than as nominal, and the age and storage history of the stock; differences in any of these can explain a discrepancy without any difference in the underlying biology. Handling those four items as a standard comparison list keeps disagreements productive.

Related reading

Frequently asked questions

What is IGF-1 LR3 in one sentence?

An 83-residue recombinant analog of IGF-1, with Arg at position 3 and a 13-residue N-terminal extension, designed to bind IGF-binding proteins weakly.

Is IGF-1 LR3 the same as IGF-1?

No. Native IGF-1 has 70 residues and binds binding proteins strongly. The analog is longer, changed at position 3 and binds them weakly.

What is the main laboratory use?

As a growth-factor input in cell culture, especially in low-serum or serum-free systems, and as a ligand for studying IGF-1 receptor signaling.

Which pathways does it activate in cell models?

The same as native IGF-1: PI3K/Akt and Ras/MAPK downstream of the IGF-1 receptor.

Why do papers report higher potency than native IGF-1?

Because binding proteins capture native IGF-1 in many systems and the analog largely avoids them. The advantage depends on how much binding protein is present.

How is the material supplied?

As a 1 mg lyophilized powder in a sealed clear glass vial, per the product page, with storage at 2–8 °C and −20 °C for long-term.

Does purity alone show a lot is good?

Not for a disulfide-bonded protein. Folding and activity also matter, so identity, folding checks and a bioassay complement the HPLC number.

How do I choose between IGF-1 LR3 and IGF-1 DES?

By the experiment: the two differ in length, potency and handling; the comparison article lays out the differences.

Is there any claim about use outside the laboratory?

No. This guide and the product are for laboratory research use only and make no claims about human or animal use.

Where do I start reading?

The research overview for background, then the topic articles listed in the reading list above.

Related reading: IGF-1 LR3 Storage & Stability: Degradation Routes, IGF-1 LR3 Structure: Sequence Changes Explained, IGF-1 and Tissue Repair Research: What Models Show.

References

  1. Laron Z. Insulin-like growth factor 1 (IGF-1): a growth hormone. Mol Pathol. 2001;54(5):311-316. doi:10.1136/mp.54.5.311
  2. Baxter RC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab. 2000;278(6):E967-E976. doi:10.1152/ajpendo.2000.278.6.e967
  3. Bayne ML, Applebaum J, Chicchi GG, et al. Structural analogs of human insulin-like growth factor I with reduced affinity for serum binding proteins and the type 2 IGF receptor. J Biol Chem. 1988;263(13):6233-6239. doi:10.1016/s0021-9258(18)68777-0
  4. Tomas FM, Knowles SE, Owens PC, et al. Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats. Biochem J. 1992;282:91-97. doi:10.1042/bj2820091
  5. Tomas FM, Knowles SE, Chandler CS, Francis GL, Owens PC, Ballard FJ. Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in normal female rats. J Endocrinol. 1993;137(3):413-421. doi:10.1677/joe.0.1370413
  6. Hakuno F, Takahashi SI. 40 years of IGF1: IGF1 receptor signaling pathways. J Mol Endocrinol. 2018;61(1):T69-T86. doi:10.1530/jme-17-0311
  7. Rommel C, Bodine SC, Clarke BA, et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol. 2001;3(11):1009-1013. doi:10.1038/ncb1101-1009
  8. Freedman LP, Cockburn IM, Simcoe TS. The economics of reproducibility in preclinical research. PLoS Biol. 2015;13(6):e1002165. doi:10.1371/journal.pbio.1002165

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.